Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis

Hepatology

Volumn 25, Issue 2, 1997, Pages 317-323

  Czaja, Albert J ^a   Strettell, Michael D J ^b   Thomson, Linda J ^b   Santrach, Paula J ^a   Moore, S Breanndan ^a   Donaldson, Peter T ^b   Williams, Roger ^b  

^a MAYO CLINIC   (United States)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PREDNISONE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DISEASE PREDISPOSITION; FEMALE; HEPATITIS; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031032711     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250211     Document Type: Article

References (40)

1. Williams RM, Martin S, Falchuk KR, Trey C, Dubey DP, Cannady WG, Fitzpatrick D, et al. Increased frequency of HLA-DRW4 in chronic active hepatitis. Vox Sang 1978;35:366-369.
2. Mackay IR, Tait BD. HLA associations with autoimmune-type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies. Gastroenterology 1980;79:95-98.
3. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. HEPATOLOGY 1991;13:701-716.
4. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. HEPATOLOGY 1993;18:816-822.
5. Czaja AJ, Santrach PJ, Moore SB. HLA DQ associations in type 1 autoimmune hepatitis. Mayo Clin Proc 1995;70:1154-1160.
6. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105:1502-1507.
7. Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. HEPATOLOGY 1994;19:609-615.
8. Czaja AJ, Rakela J, Hay JE, Moore SB. Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1990;98:1587-1593.
9. Opelz G, Vogten AJM, Summerskill WHJ, Schalm SW, Terasaki PI. HLA determinants in chronic active liver disease: possible relation of HLA-Dw3 to prognosis. Tissue Antigens 1977;9:36-40.
10. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. HEPATOLOGY 1992;15: 215-221.
11. Bodmer JG, Marsh SGE, Albert ED, Bodmer WF, Bontrop RE, Charron D, Dupont B, et al. Nomenclature for factors of the HLA system, 1995. Hum Immunol 1995;43:149-164.
12. Strettell MDJ, Czaja AJ, Donaldson PT, Williams R. Genetic susceptibility to autoimmune hepatitis (AIH) [Abstract]. HEPATOLOGY 1995;22:A128.
13. Strettell MDJ, Czaja AJ, Thomson LJ, Santrach PJ, Moore SB, Williams R, Donaldson PT. Susceptibility to autoimmune hepatitis (AIH) is determined by a lysine residue at position 71 of the DRβ polypeptide chain [Abstract]. Gastroenterology 1996;110:A1335.
14. Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995;40:435-456.
15. Johnson PJ, McFarlane IG, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, Chapman RW, et al. Meeting Report. International Autoimmune Hepatitis Group. HEPATOLOGY 1993;18:998-1005.
16. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992;103:1290-1295.
17. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983;85:713-717.
18. Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994;107:200-207.
19. Czaja AJ. Autoimmune chronic active hepatitis - a specific entity? The negative argument. J Gastroenterol Hepatol 1990;5:343-351.
20. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824-1832.
21. Czaja AJ. Autoimmune hepatitis: current therapeutic concepts. Clin Immunother 1994;1:413-429.
22. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-883.
23. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-235.
24. Vergani D, Wells L, Larcher VF, Nasaruddin BA, Davies ET, Mieli-Vergani G, Mowat AP. Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis. Lancet 1985;2:294-298.
25. Scully LJ, Toze C, Sengar DPS, Goldstein R. Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology 1993; 104:1478-1484.
26. Doherty DG, Underhill JA, Donaldson PT, Manabe K, Mieli-Vergani G, Eddleston ALWF, Vergani D, et al. Polymorphisms in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis. Autoimmunity 1994;18:243-249.
27. Manns MP, Kruger M. Immunogenetics of chronic liver diseases. Gastroenterology 1994;106:1676-1697.
28. Donaldson P, Doherty D, Underhill J, Williams R. The molecular genetics of autoimmune liver disease. HEPATOLOGY 1994;20:225-239.
29. Ollier W. Shock revelations about HLA-DR4: a short cut to rheumatoid arthritis. Nat Med 1996;2:279-280.
30. Todd JA, Bell JI, McDevitt HO. HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987; 329:599-604.
31. Ben Ari Z, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995;23:351-354.
32. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-1378.
33. Payami H, Khan MA, Grennan DM, Sanders PA, Dyer PA, Thomson G. Analysis of genetic interrelationship among HLA-associated diseases. Am J Hum Genet 1987;41:331-349.
34. Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996;41:305-314.
35. Griffing WL, Moore SB, Luthra HS, McKenna CH, Fathman CG. Associations of antibodies to native DNA with HLA-DRw3: a possible major histocompatibility complex-linked human immune response gene. J Exp Med 1980;152:319s-325s.
36. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 1996;24:52-59.
37. Rees AJD, Peters DK, Compston DAS, Batchelor JR. Strong association between HLA-DRw2 and antibody-mediated Goodpasture's syndrome. Lancet 1978;1:966-968.
38. Naeim F, Keesey JC, Herrmann C Jr, Lindstrom J, Zeller E, Walford RL. Association of HLA-B8, Drw3, and anti-acetylcholine receptor antibodies in myasthenia gravis. Tissue Antigens 1978;12:381-386.
39. Tan EM. Antinuclear antibodies. Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;44:93-151.
40. Czaja AJ. Autoantibodies. Baillieres Clin Gastroenterol 1995;9:723-744.